Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06050291 · ClinicalTrials.gov registry record · Phase 1
Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe
A Phase 1 study, sponsored by NewAmsterdam Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT06050291: Completed Phase 1 study, sponsored by NewAmsterdam Pharma.
NCT06050291 is a Phase 1 study that has completed, run by NewAmsterdam Pharma. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06050291, a Phase 1 study, has completed, sponsored by NewAmsterdam Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will assess the effect of food on the bioavailability of obicetrapib and ezetimibe after a single-dose administration of a fixed-dose combination formulation of obicetrapib/ezetimibe, 10 mg/10 mg in healthy adult male and female subjects under fasted and fed conditions.
Primary Outcome
Maximum measured plasma concentration following each treatment.
Interventions
- DRUG Fixed-Dose Combination (FDC) Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-01-20 |
| Est. Completion | 2024-04-07 |
| Phase | Phase 1 |
What the finished NCT06050291 record still lists
NCT06050291 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 0 conditions, and to 1 intervention - of which Fixed-Dose Combination (FDC) Tablet is the first listed.
NCT06050291 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06050291 about?
NCT06050291 is a clinical study titled "Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe". This study will assess the effect of food on the bioavailability of obicetrapib and ezetimibe after a single-dose administration of a fixed-dose combination formulation of obicetrapib/ezetimibe, 10 mg/10 mg in healthy adult male and female subjects under fasted and fed conditions.
What is the current status of trial NCT06050291?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2024-01-20. Estimated completion is 2024-04-07.
What interventions are being tested in trial NCT06050291?
The interventions under investigation include: Fixed-Dose Combination (FDC) Tablet (DRUG).
Who is sponsoring clinical trial NCT06050291?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06050291's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI